Literature DB >> 10658603

A comparative molecular field analysis and molecular modelling studies on pyridylimidazole type of angiotensin II antagonists.

S E Yoo1, S K Kim, S H Lee, K Y Yi, D W Lee.   

Abstract

A large number of compounds known as "AII (Angiotensin II) antagonists" have been developed for the treatment of various heart diseases such as hypertension, congestive heart failure, and chronic renal failure. Most of the currently known AII receptor antagonists share a similar chemical structure, consisting of nitrogen atoms, a lipophilic alkyl side chain and an acidic group. As a new series, we have designed and synthesized various pyridylimidazole derivatives. In this report we would like to discuss the structure-activity relationship of these series of compounds using the comparative molecular field analysis (CoMFA) methods. We could come up with a good CoMFA model (cross-validated and conventional r2 values equal to 0.702 and 0.991, respectively) and the validity of the model was confirmed by synthesizing and measuring their biological activity of additional 6 compounds suggested by the model. This result provides additional information on the structural requirement for structurally diverse group of AII receptor antagonists.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10658603     DOI: 10.1016/s0968-0896(99)00245-x

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  1 in total

1.  TM-25659 enhances osteogenic differentiation and suppresses adipogenic differentiation by modulating the transcriptional co-activator TAZ.

Authors:  E J Jang; H Jeong; J O Kang; N J Kim; M S Kim; S H Choi; S E Yoo; J H Hong; M A Bae; E S Hwang
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.